You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

refractory hairy cell leukemia

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hairy Cell Leukemia, Hairy Cell Leukemia Variant Trial run by the NCI (CD22CART cell infusion)

Recruiting
  • Hairy Cell Leukemia
  • Hairy Cell Leukemia Variant
  • CD22CART cell infusion
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 25, 2023

Relapsed/Refractory Waldenstrom Macroglobulinemia, Relapsed/Refractory Richter Transformation, Relapsed/Refractory Burkitt

Not yet recruiting
  • Relapsed/Refractory Waldenstrom Macroglobulinemia
  • +3 more
  • Brexucabtagene Autoleucel
  • +2 more
  • (no location specified)
Sep 8, 2022

Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Blastic Plasmacytoid Dendritic Cell Tumor Trial in

Recruiting
  • Recurrent Acute Leukemia
  • +16 more
  • Duarte, California
    City of Hope Medical Center
Nov 22, 2022

Hairy Cell Leukemia Trial in La Jolla (Low dose vemurafenib plus rituximab)

Recruiting
  • Hairy Cell Leukemia
  • Low dose vemurafenib plus rituximab
  • La Jolla, California
    Scripps MD Anderson Cancer Center
May 19, 2022

Patients Previously Treated WithMustang Bio CAR-T Cell

Enrolling by invitation
  • Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
  • +10 more
  • Prior MB-102 CAR-T cell investigational product.
  • Prior MB-106 CAR-T cell investigational product.
  • Duarte, California
  • +4 more
Dec 8, 2022

Adult Grade III Lymphomatoid Granulomatosis, Cutaneous B-cell Non-Hodgkin Lymphoma, MALT Trial in Duarte (biological, procedure,

Active, not recruiting
  • Adult Grade III Lymphomatoid Granulomatosis
  • +23 more
  • autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells
  • +2 more
  • Duarte, California
    City of Hope Medical Center
Jan 4, 2023

Leukemia, Acute Myeloid, MDS, Classical Hodgkin Lymphoma Trial in United States (MGD024)

Recruiting
  • Leukemia, Acute Myeloid
  • +7 more
  • Denver, Colorado
  • +4 more
Aug 29, 2022

CLL/SLL, Waldenstrom Macroglobulinemia, Follicular Lymphoma Trial in Cincinnati, Columbus, Salt Lake City (LP-168)

Recruiting
  • CLL/SLL
  • +6 more
  • Cincinnati, Ohio
  • +2 more
May 7, 2022

Relapsed/Refractory Hairy Cell Leukemia Trial (Moxetumomab Pasudotox)

Approved for marketing
  • Relapsed/Refractory Hairy Cell Leukemia
  • Moxetumomab Pasudotox
  • (no location specified)
Jun 26, 2020

Hairy Cell Leukemia Patients

Not yet recruiting
  • Hairy Cell Leukemia
    • (no location specified)
    May 5, 2023

    Hairy Cell Leukemia Trial run by the NCI (Moxetumomab Pasudotox-tdfk, Rituximab, Ruxience)

    Active, not recruiting
    • Hairy Cell Leukemia
    • Moxetumomab Pasudotox-tdfk
    • +2 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 26, 2023

    Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in

    Active, not recruiting
    • Accelerated Phase Chronic Myelogenous Leukemia
    • +125 more
    • tetanus-CMV fusion peptide vaccine
    • laboratory biomarker analysis
    • Duarte, California
      City of Hope Medical Center
    Feb 28, 2022

    Anemia, B-Cell Prolymphocytic Leukemia, Grade 1 Follicular Lymphoma Trial in Portland (drug, other, biological)

    Completed
    • Anemia
    • +13 more
    • Portland, Oregon
      OHSU Knight Cancer Institute
    Apr 29, 2021

    Hairy Cell and Other Leukemias, and to Develop Recombinant

    Recruiting
    • Hairy Cell Leukemia (HCL)
    • +4 more
      • Bethesda, Maryland
        National Institutes of Health Clinical Center, 9000 Rockville Pi
      Aug 24, 2022

      Moxetumomab Pasudotox-tdfk (LUMOXITI)

      Recruiting
      • Hairy Cell Leukemia
        • Pueblo, Colorado
        • +1 more
        Aug 17, 2022

        Hairy Cell Leukemia Trial run by the NCI (Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin)

        Active, not recruiting
        Has Results
        • Hairy Cell Leukemia
        • Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin
        • Bethesda, Maryland
          National Institutes of Health Clinical Center, 9000 Rockville Pi
        Apr 13, 2022

        Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With

        Active, not recruiting
        • Adult Acute Lymphoblastic Leukemia in Remission
        • +46 more
        • Philadelphia, Pennsylvania
          Thomas Jefferson University
        Feb 10, 2021

        Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Burkitt Lymphoma

        Completed
        Has Results
        • Adult Grade III Lymphomatoid Granulomatosis
        • +88 more
        • Detroit, Michigan
          Barbara Ann Karmanos Cancer Institute
        Apr 14, 2021

        Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma

        Terminated
        Has Results
        • Adult Grade III Lymphomatoid Granulomatosis
        • +116 more
        • brentuximab vedotin
        • +2 more
        • Chicago, Illinois
        • +2 more
        Aug 30, 2021

        Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Tumor (BPDCN), Relapse Leukemia Trial in Taiyuan (CD123 targeted

        Recruiting
        • Acute Myeloid Leukemia
        • +3 more
        • CD123 targeted CAR-NK cells
        • Taiyuan, Shanxi, China
          Shanxi Bethune Hospital
        Aug 28, 2023

        B-cell Acute Lymphoblastic Leukemia Trial in Hefei (QH103 Cell Injection, Fludarabine, Cyclophosphamide)

        Recruiting
        • B-cell Acute Lymphoblastic Leukemia
        • QH103 Cell Injection
        • +2 more
        • Hefei, Anhui, China
          Anhui Provincial Hospital
        Sep 21, 2023

        Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse Trial in Xuzhou (anti Tim-3/CD123 CAR-T cell therapy)

        Recruiting
        • Acute Myeloid Leukemia Refractory
        • Acute Myeloid Leukemia, in Relapse
        • anti Tim-3/CD123 CAR-T cell therapy
        • Xuzhou, Jiangsu, China
          Kailin Xu
        Nov 4, 2023

        Relapsed or Refractory CD19+ B-cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small

        Recruiting
        • Relapsed or Refractory CD19+ B-cell Lymphoma
        • +2 more
        • TBI-2001
        • +2 more
        • Toronto, Ontario, Canada
          Princess Margaret Cancer Centre
        Jul 26, 2023

        Extranodal NK T Cell Lymphoma, NK-Cell Leukemia Trial in Xuzhou (Anti-CD56 CAR T)

        Recruiting
        • Extranodal NK T Cell Lymphoma
        • NK-Cell Leukemia
        • Anti-CD56 CAR T
        • Xuzhou, Jiangsu, China
          The Affiliated Hospital of Xuzhou Medical University
        Jul 10, 2023

        Relapsed and/or Refractory Multiple Myeloma, Plasma Cell Leukemia in Relapse Trial in Shanghai (Biological)

        Recruiting
        • Relapsed and/or Refractory Multiple Myeloma
        • Plasma Cell Leukemia in Relapse
        • Biological
        • Shanghai, Shanghai, China
          Shanghai Tongji Hospital
        May 29, 2023